Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)

Trial Profile

Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Binge-Eating Disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2016 Status changed from recruiting to completed.
    • 04 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top